Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.

Geraldine Helen O'Sullivan Coyne,Khanh Tu Do,Shivaani Kummar,Naoko Takebe,Mary Flanagan Quinn,Sarina Anne Piha-Paul,Ashley Bruns,Lamin Juwara,Elad Sharon,Richard Piekarz,Howard Streicher,Larry Rubinstein,Deborah Wilsker,Robert J. Kinders,Ralph E. Parchment,E. Levy,Austin Doyle,James H. Doroshow,Alice P. Chen

Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.

2018

Geraldine Helen O'Sullivan Coyne
Khanh Tu Do
Shivaani Kummar
Naoko Takebe
Mary Flanagan Quinn
Sarina Anne Piha-Paul
Ashley Bruns
Lamin Juwara
Elad Sharon
Richard Piekarz
Howard Streicher
Larry Rubinstein
Deborah Wilsker
Robert J. Kinders
Ralph E. Parchment
E. Levy
Austin Doyle
James H. Doroshow
Alice P. Chen

2549Background: Ataxia-telangiectasia-related (ATR) protein kinase is central to the repair of damaged DNA through the homologous recombination (HR) pathway, activating phosphorylation cascades tha...

Keywords:

Veliparib
Cisplatin
Cancer research
Pathology
Medicine
Homologous recombination
Protein kinase A
in patient
Phosphorylation
DNA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations